Los Angeles, July 6, 2020— Proskauer, a leading international law firm, announced today that it secured a victory on behalf of client Amgen in the Federal Circuit.

The decision addresses a novel issue of law regarding the Biologics Price Competition and Innovation Act notice requirements to be able to launch a biosimilar product into the market. Proskauer defeated Genentech’s motions to keep Amgen’s Mvasi biosimilar off the market.

Proskauer’s team at the Federal Circuit was led by partners Siegmund Gutman (Life Sciences) and John Roberts (Litigation), and included senior counsel, Amir Naini, and associates, Sarah Cork and Kimberly Li.

Proskauer’s multidisciplinary Life Sciences Group brings together the critical skill sets and experience to litigate important intellectual property matters, create and grow life sciences companies, obtain intellectual property rights, raise capital and negotiate and execute strategic deals.

We represent mature pharma and biotech companies in accessing and protecting markets, early-to-later-stage companies in developing new medical technologies, investors in their strategic transactions, as well as universities and other academic or research institutions in realizing commercial value from the innovation of their faculty and research staff. The myriad connections we have in this sector allow us to help clients grow their businesses by gaining access to financing, technology, partners and markets.